Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GBT

DatePrice TargetRatingAnalyst
8/8/2022Outperform → Mkt Perform
William Blair
8/8/2022$40.00 → $72.00Hold → Buy
Canaccord Genuity
3/28/2022$138.00 → $71.00Outperform
Wedbush
2/28/2022$28.00 → $31.00Equal-Weight
Morgan Stanley
2/24/2022$92.00 → $86.00Outperform
Oppenheimer
12/21/2021$56.00 → $53.00Outperform
SVB Leerink
12/14/2021$54.00 → $56.00Outperform
SVB Leerink
12/7/2021Market Perform → Outperform
William Blair
More analyst ratings

$GBT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

    Issues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom Highlights Concerns that Company's Misguided Acquisition Strategy Will Destroy Value and Prevent Dynavax from Maximizing the Benefit of Heplisav for Shareholders and Patients In Deep Track's View, Focusing on Heplisav Could Result in Nearly $2 Billion of Cash Being Returned to Shareholders by the End of 2030 Details Board's Poor Governance, Reactive Entrenchment Maneuvers, and Unwillingness to Work Constructively Believes Its Slate of Director Nominees Would Collectively Bring Valuable Shareholder Perspective and Independence as Well

    $AVTE
    $DVAX
    $HZNP
    $MRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022

    SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced today and, if passed in its current form, would authorize for appropriations of $535 million in annual funding to support sickle cell disease (SCD) treatment, research and education. The new legislation is sponsored by Congresswoman Barbara Lee of California, Congressman Danny Davis of Illinois, Senator Chris Van Hollen of Maryland and Senator Cory Booker of New Jersey. The bill would create a national network of SCD treatment centers in which healthcare providers and communit

    $GBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference

    SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 11th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Wednesday, September 14th. The virtual conference, which takes place during National Sickle Cell Awareness Month, is open to the public and will be live streamed on the SCD Therapeutics Conference website and the Facebook page of Sickle Cell Warriors, an SCD community organization. Admiral Rachel Levine, M.D., assistant secretary for health, U.S. Department of Health and Human Services (HHS), will provide remarks at the

    $GBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GBT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$GBT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GBT
SEC Filings

See more

$GBT
Leadership Updates

Live Leadership Updates

See more
  • GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors

    SOUTH SAN FRANCISCO, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Alexis A. Thompson, M.D., M.P.H., a world-renowned hematologist and sickle cell disease (SCD) expert, to the company’s board of directors. Dr. Thompson, who brings decades of experience in clinical research, patient care, leadership and advocacy in hematology, will serve on the board’s research and development committee. “We’re thrilled to welcome Alexis to our board as we continue to pursue the transformation of care in sickle cell disease,” said Ted W. Love, M.D., president and chief executive officer of GBT. “Her deep expertise in blood

    $GBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GBT Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on January 1, 2021, the compensation committee of GBT’s board of directors granted six new employees restricted stock units for an aggregate of 27,500 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT’s board of dire

    $GBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GBT Appoints Kim Smith-Whitley, M.D., to Lead Research and Development

    SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that world-renowned hematologist and sickle cell disease (SCD) thought leader and advocate Kim Smith-Whitley, M.D., will join the company as executive vice president and head of research and development. “As we enter a period of expected sustained growth for years to come, aligning our research and development teams under a single leader will make GBT even more efficient and productive in bringing innovative medicines to patients. We are absolutely thrilled to add Kim, a committed and accomplished global leader in sickle cell disease, to our senior management

    $GBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GBT
Financials

Live finance-specific insights

See more
  • Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology

    Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics share in cash, for a total enterprise value of approximately $5.4 billion NEW YORK and SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE:PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmace

    $GBT
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022

    SOUTH SAN FRANCISCO, Calif., July 29, 2022 (GLOBE NEWSWIRE) --  Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after U.S. financial markets close. Management will host a conference call on Monday, August 8, 2022, at 4:30 p.m. ET to discuss second quarter 2022 financial results and to provide a business update. To participate in the conference call, please dial 877-407-3982 (domestic) or +1 201-493-6780 (international). A live audio webcast can be accessed on GBT's website at www.gbt.com in the Investors section. The archived audio webcast will be available for one month following the e

    $GBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease

    Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year GBT to hold investor conference call and webcast today at 3:00 p.m. CEST (9:00 a.m. EDT) to highlight EHA data and provide business updates SOUTH SAN FRANCISCO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new data from a large multicenter real-world evidence study supporting the clinical use of Oxbryta® (voxelotor) for the treatment of sickle cell disease (SCD) in patients 12 years of age and older. In addition, Phase 1 data of GBT021601 (GBT601), the company's next-generation sickle hemo

    $GBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GBT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more